Iovance Biotherapeutics, Inc. $IOVA Shares Sold by Profund Advisors LLC

Profund Advisors LLC cut its position in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) by 29.0% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 62,848 shares of the biotechnology company’s stock after selling 25,691 shares during the period. Profund Advisors LLC’s holdings in Iovance Biotherapeutics were worth $108,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also modified their holdings of the company. Vanguard Group Inc. lifted its holdings in Iovance Biotherapeutics by 0.9% during the 1st quarter. Vanguard Group Inc. now owns 27,777,778 shares of the biotechnology company’s stock worth $92,500,000 after buying an additional 243,438 shares during the last quarter. Long Focus Capital Management LLC raised its holdings in Iovance Biotherapeutics by 80.2% during the first quarter. Long Focus Capital Management LLC now owns 9,250,055 shares of the biotechnology company’s stock worth $30,803,000 after purchasing an additional 4,118,055 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its holdings in shares of Iovance Biotherapeutics by 202.8% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 5,777,344 shares of the biotechnology company’s stock valued at $19,239,000 after buying an additional 3,869,617 shares in the last quarter. Goldman Sachs Group Inc. raised its stake in Iovance Biotherapeutics by 30.5% during the 1st quarter. Goldman Sachs Group Inc. now owns 5,571,902 shares of the biotechnology company’s stock worth $18,554,000 after acquiring an additional 1,301,846 shares in the last quarter. Finally, Invenomic Capital Management LP acquired a new position in Iovance Biotherapeutics in the first quarter valued at $18,281,000. 77.03% of the stock is owned by hedge funds and other institutional investors.

Iovance Biotherapeutics Price Performance

Shares of NASDAQ:IOVA opened at $2.47 on Monday. Iovance Biotherapeutics, Inc. has a 12 month low of $1.64 and a 12 month high of $9.70. The firm has a market capitalization of $980.52 million, a price-to-earnings ratio of -2.06 and a beta of 0.87. The business’s 50 day simple moving average is $2.21 and its 200-day simple moving average is $2.24.

Iovance Biotherapeutics (NASDAQ:IOVA) last posted its earnings results on Thursday, November 6th. The biotechnology company reported ($0.25) EPS for the quarter, topping analysts’ consensus estimates of ($0.29) by $0.04. The company had revenue of $67.46 million for the quarter, compared to the consensus estimate of $76.20 million. Iovance Biotherapeutics had a negative return on equity of 55.24% and a negative net margin of 158.78%. Iovance Biotherapeutics has set its FY 2025 guidance at EPS. On average, equities analysts anticipate that Iovance Biotherapeutics, Inc. will post -1.24 earnings per share for the current year.

Analysts Set New Price Targets

IOVA has been the topic of several research analyst reports. Wells Fargo & Company cut their price target on Iovance Biotherapeutics from $18.00 to $14.00 and set an “overweight” rating on the stock in a research report on Friday, August 8th. Chardan Capital decreased their price objective on Iovance Biotherapeutics from $20.00 to $17.00 and set a “buy” rating for the company in a research report on Thursday, November 6th. HC Wainwright lowered their price objective on shares of Iovance Biotherapeutics from $20.00 to $9.00 and set a “buy” rating on the stock in a research report on Wednesday, October 29th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Iovance Biotherapeutics in a report on Wednesday, October 8th. Finally, Zacks Research raised shares of Iovance Biotherapeutics to a “hold” rating in a report on Tuesday, August 12th. Six research analysts have rated the stock with a Buy rating, seven have issued a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Iovance Biotherapeutics currently has an average rating of “Hold” and an average target price of $10.50.

Iovance Biotherapeutics Company Profile

Iovance Biotherapeutics, Inc, a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma.